Setting The Stage For Successful Clinical Manufacturing Of Cell And Gene Therapies

While early-stage biotech companies might feel the competitive pressure to rush their novel cell and gene therapies into clinical trials, allocating the time and resources to thoroughly and objectively assess both their own readiness and where and how to manufacture is a critical step to avoid common mistakes and maximize the therapy’s potential for success. In this webinar, a panel of industry experts discuss the common pitfalls for therapy developers and the key indicators of GMP readiness for manufacturing processes.

A significant amount of work needs to be done prior to clinical manufacturing, such as defining the product profile and corresponding specifications. There are tempting shortcuts at this stage, but establishing your product profile is an essential step to transfer your product for manufacturing and bears significant impact on the CDMO’s work to successfully execute the process. Assessing your product, capabilities, technologies, processes, and team, as well as your ability to build a successful CDMO relationship, is a key step to ensure quality, improve patient access, and reduce the cost of manufacturing. Learn more as this panel explores how to best prepare for success while bringing your product from the bench to patients worldwide.